A randomized, double-blind, adaptive single-ascending-dose SAD/MAD/FE phase I study of RG-7816 in healthy volunteers

Trial Profile

A randomized, double-blind, adaptive single-ascending-dose SAD/MAD/FE phase I study of RG-7816 in healthy volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs RG-7816 (Primary)
  • Indications Autistic disorder
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top